Vical Inc. and Astellas Pharma Inc.'s cytomegalovirus (CMV) therapeutic vaccine ASP0113 (formerly TransVax) has failed to meet its primary endpoint in a 150-patient Phase II study in CMV-seronegative patients receiving a kidney transplant from a CMV-seropositive donor.
Stumble For Vical/Astellas CMV Vaccine In Kidney Transplants
Vical and Astellas have unveiled disappointing topline Phase II results with their cytomegalovirus vaccine in kidney transplant patients, although the product remains on track in the hematopoietic cell transplant setting.
